The yearly production amount of COVID-19 vaccines in China might reach an estimated 610 million doses as 2020 ends, revealed China’s  National Health Commission.

Further predictions project a one billion vaccine production doses yearly 2021 onwards. This information was provided to a news briefing by Zheng Zhongwei, director General of the Development Centre for Medical Science and Technology of the commission. 

More information on Thursday from a Chinese pharmaceutical company suggested the COVID-19 vaccine under development should be available for worldwide distribution early 2021 onwards, including the USA. 

Yin Weidong, the CEO of SinoVac, vowed to apply to the US Food and Drug Administration to sell CoronaVac in the United States should it pass its third and final round of testing in humans. The Sinovac developed vaccine alongside state-owned SinoPharm is among the four main candidates in China. Sinopharm includes two in development and military-affiliated private firm CanSino. There is over 24,000 vaccine testing volunteers CoronaVac in Brazil, Turkey, and Indonesia.